U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck's PREVYMIS for Prophylaxis of Cytomegalovirus Disease in Kidney Transplant Recipients at High Risk Pharmaceutical Investing
Merck's KEYTRUDA® Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma Regardless of PD-L1 Expression Pharmaceutical Investing
Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium Pharmaceutical Investing
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study Pharmaceutical Investing
Basketball Legend Kareem Abdul-Jabbar Joins No Time to Wait Campaign to Raise Awareness of Atrial Fibrillation and its Symptoms Pharmaceutical Investing
Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults Pharmaceutical Investing
Johnson & Johnson Names Paula A. Johnson, President of Wellesley College, to its Board of Directors Pharmaceutical Investing
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE , Oak Street Health , Argo Group International Holdings, Ltd. , Cardiovascular Systems, Inc. Pharmaceutical Investing
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023 Pharmaceutical Investing
Johnson & Johnson to Participate in the Barclays Global HealthCare Conference Pharmaceutical Investing
Opdivo® in Combination with CABOMETYX® Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Pharmaceutical Investing
